002826 易明医药
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)5.3732.0656.0356.0486.140
总资产报酬率 ROA (%)4.2831.5814.7904.9034.714
投入资产回报率 ROIC (%)5.2711.9715.7715.5715.094

边际利润分析
销售毛利率 (%)66.28151.18943.90835.90935.964
营业利润率 (%)13.1833.5246.5056.7047.156
息税前利润/营业总收入 (%)12.9053.3136.4356.7417.967
净利润/营业总收入 (%)11.3412.3585.3835.9936.819

收益指标分析
经营活动净收益/利润总额(%)43.71782.08860.71042.46548.394
价值变动净收益/利润总额(%)1.8019.8002.6121.8131.154
营业外收支净额/利润总额(%)-0.3700.4011.7162.7528.917

偿债能力分析
流动比率 (X)2.7012.8622.1953.6462.063
速动比率 (X)2.5152.5182.0213.3071.968
资产负债率 (%)20.30619.15226.34112.65824.330
带息债务/全部投入资本 (%)1.0571.0426.2170.789--
股东权益/带息债务 (%)9,281.2279,411.0951,495.80312,480.998641.755
股东权益/负债合计 (%)389.638419.293277.879687.402311.009
利息保障倍数 (X)-56.255-14.698-35.132-44.16272.375

营运能力分析
应收账款周转天数 (天)34.07751.74741.85923.4510.000
存货周转天数 (天)70.39457.78529.65121.0240.000